Sanofi Q4 business profit rises 18.4%Christian Fernsby ▼ | February 6, 2020
Sanofi eported that its fourth quarter business earnings per share rose 17.3% at CER to 1.34 euros.
Sanofi Business net income was at 1.68 billion euros, an increase of 18.4%
On an IFRS basis, the company reported a net loss of 10 million euros.
Fourth-quarter net sales were 9.61 billion euros, up 6.8% on a reported basis and 4.7% at CER, driven by Dupixent and Vaccines.
Vaccines sales increased 22.0%, reflecting majority of U.S.
influenza vaccine shipments in the fourth quarter.
Full year 2019 business earnings per share was 5.99 euros, up 6.8% at CER.
Net sales were 36.13 billion euros, up 4.8% on a reported basis and 2.8% at CER (up 3.6% at CER/CS).
Sanofi expects 2020 business earnings per share to grow around 5% at CER.
The Board proposed annual dividend of 3.15 euros. ■